All I know about E7820 is an oral anti-angiogenisis drug, which means that it is the same type of drug as Avastin. I think it has also been in trials for other types of cancer too.
I am guessing that he is on the phase II trial at USC? That would mean that he hasn't previously had Erbitux in any treatment, right? I don't know the answer, but I would ask why a phase II clinical trial without trying a combo + Erbitux first.
Knowing that he has liver mets, I would also ask how the E7820 might keep him from using chemoembolization and/or SirSpheres to the liver later. I don't konw enough about E7820 to know the possible complications, but I know that taking Avastin can "close up" blood vessels too much to make chemoembolization or SirSpheres effective. Since hopefully the idea is to shrink the tumors enough to be dealt with in another way, I would think that he would want to make sure that option is still available.
Sorry I don't know more about E7820, and I don't remember your friend's entire story, or maybe I would have more answers!
p.s. The trial I am thinking he is on would be the one with the ClinicalTrials.gov ID #NCT00309179 (Study ID Number E7820-A001-204).
Hannah K. Vogler
Co-Founder, The Colon Club
cousin of Amanda Sherwood Roberts
dx 1/99 Stage III at age 24
died January 1, 2002 at age 27